Sabra Health Care REIT (SBRA) EBITDA Margin (2016 - 2026)

Sabra Health Care REIT's EBITDA Margin history runs 11 years deep, the most recent figure standing at 30.59% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 624.0% year-over-year to 30.59% in Q1 2026; TTM through Mar 2026 was 89.59%, a 3651.0% increase from a year earlier, with the FY2025 full-year figure at 74.51%, down 1102.0% from the prior year.
• EBITDA Margin grew to 30.59% in Q1 2026 per SBRA's latest filing, from 26.69% in the prior quarter.
• Across five years, EBITDA Margin topped out at 162.66% in Q1 2022 and bottomed at 26.69% in Q4 2025.
• The 5-year median for EBITDA Margin is 36.35% (2023), against an average of 47.34%.
• Across the five-year window, EBITDA Margin jumped 12095 bps in 2022 and plunged 14487 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 59.57% in 2022, then sank by 83 bps to 10.14% in 2023, then surged by 1066 bps to 118.18% in 2024, then plunged by 123 bps to 26.69% in 2025, then jumped by 215 bps to 30.59% in 2026.
• Per Business Quant, the three latest SBRA EBITDA Margin figures stand at 30.59% (Q1 2026), 26.69% (Q4 2025), and 55.02% (Q3 2025).